Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
recombinant fowlpox-CEA(6D)/TRICOM vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00048893 | Nov 2002 → Jun 2011 | breast cancer, metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-CEA(6D)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00048893 ↗ |
| Modality | Vaccine | “two tumor-specific, recombinant, poxvirus-based deoxyribonucleic acid (DNA) Tricom vaccines” NCT00048893 ↗ |
| Route | Subcutaneous | “4 x 10^8 pfu given monthly subcutaneously” NCT00048893 ↗ |